Abstract
Gut dysbiosis and liver cirrhosis are two corelated complications that highly disturbs the metabolism of a normal human body. Liver cirrhosis is scarring of the hepatic tissue and gut dysbiosis is the imbalance in the microbiome of the gut. Gut dysbiosis in cirrhosis occurs due to increased permeability of the intestinal membrane which might induce immune responses and damage the normal functioning of the body. Dysbiosis can cause liver damage from cirrhosis and can further lead to liver failure by hepatocellular carcinoma. In this review we discuss if eubiosis can revert the poorly functioning cirrhotic liver to normal functioning state? A normal microbiome converts various liver products into usable forms that regulates the overgrowth of microbiome in the gut. The imbalance caused by dysbiosis retards the normal functioning of liver and increases the complications. To correct this dysbiosis, measures like use of antibiotics with probiotics and prebiotics are used. This correction of the gut microbiome serves as a ray of hope to recover from this chronic illness. In case of alcohol induced liver cirrhosis, intervention of microbes can possibly be helpful in modulating the addiction as well as associated complications like depression as microbes are known to produce and consume neurotransmitters that are involved in alcohol addiction. Hence a correction of gut liver brain axis using microbiome can be a milestone achieved not only for treatment of liver cirrhosis but also for helping alcohol addicts quit and live a healthy or at least a near healthy life.
Similar content being viewed by others
References
Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet (London, England) 371:838–851. https://doi.org/10.1016/S0140-6736(08)60383-9. (PMID: 18328931)
Sherlock S, Dooley J (2008) Diseases of the liver and biliary system. John Wiley & Sons
Triger DR, Wright R (1973) Hyperglobulinaemia in liver disease. Lancet (London, England) 1:1494–1496. https://doi.org/10.1016/s0140-6736(73)91827-8
Papadakis MA, Fraser CL, Arieff AI (1990) Hyponatraemia in patients with cirrhosis. Q J Med 76:675–688
Peck-Radosavljevic M, Wichlas M, Zacherl J, Stiegler G, Stohlawetz P, Fuchsjäger M, Kreil A, Metz-Schimmerl S, Panzer S, Steininger R, Mühlbacher F, Ferenci P, Pidlich J, Gangl A (2000) Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 95:795–801
Schaffner F, Poper H (1963) Capillarization of hepatic sinusoids in man. Gastroenterology 44:239–242. https://doi.org/10.1016/S0016-5085(63)80130-4
Yin C, Evason KJ, Asahina K, Stainier DY (2013) Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Investig 123:1902–1910. https://doi.org/10.1172/JCI66369
Zisser A, Ipsen DH, Tveden-Nyborg P (2021) Hepatic stellate cell activation and inactivation in nash-fibrosis-roles as putative treatment targets? Biomedicines 9:365. https://doi.org/10.3390/biomedicines9040365
Brandão DF, Ramalho LN, Ramalho FS, Zucoloto S, Martinelli A, Silva O (2006) Liver cirrhosis and hepatic stellate cells. Acta cirurgica brasileira 21:54–57. https://doi.org/10.1590/s0102-86502006000700013
Hautekeete ML, Geerts A (1997) The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Archiv Int J Pathol 430:195–207. https://doi.org/10.1007/BF01324802
Chu AL, Schilling JD, King KR, Feldstein AE (2021) The power of single-cell analysis for the study of liver pathobiology. Hepatol (Baltim Md) 73:437–448. https://doi.org/10.1002/hep.31485
Lee NY, Suk KT (2020) The role of the gut microbiome in liver cirrhosis treatment. Int J Mol Sci 22:199. https://doi.org/10.3390/ijms22010199. (PMID: 33379148)
Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R (2018) The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 15:397–411
Fukui H (2017) Gut microbiome-based therapeutics in liver cirrhosis: basic consideration for the next step. J Clin Transl Hepatol 5:249–260
Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS (2014) Bile acids and the gut microbiome. Curr Opin Gastroenterol 30:332–338. https://doi.org/10.1097/MOG.0000000000000057
Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A (2011) Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141:1773–1781. https://doi.org/10.1053/j.gastro.2011.07.046
Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM (2012) Linkage of gut microbiome with cognition in hepatic encephalopathy. American journal of physiology. Gastrointest Liver Physiol 302:G168–G175. https://doi.org/10.1152/ajpgi.00190.2011
Arab JP, Martin-Mateos RM, Shah VH (2018) Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hep Intl 12:24–33. https://doi.org/10.1007/s12072-017-9798-x
Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatol (Baltim Md) 54:562–572. https://doi.org/10.1002/hep.24423
Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM (2014) Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60:940–947. https://doi.org/10.1016/j.jhep.2013.12.019
Elwir S, Rahimi RS (2017) Hepatic encephalopathy: an update on the pathophysiology and therapeutic options. J Clin Transl Hepatol 5:142–151
Chen Y, Qin N, Guo J, Qian G, Fang D, Shi D, Xu M, Yang F, He Z, Van Nostrand JD, Yuan T, Deng Y, Zhou J, Li L (2014) Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics 15:753. https://doi.org/10.1186/1471-2164-15-753
Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM (2012) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. American J Physiol Gastrointest Liver Physiol 303:G675–G685. https://doi.org/10.1152/ajpgi.00152.2012
Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S (2004) Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34:2541–2550. https://doi.org/10.1002/eji.200425218
González-Navajas JM (2016) Inflammasome activation in decompensated liver cirrhosis. World J Hepatol 8:207–210. https://doi.org/10.4254/wjh.v8.i4.207
Ferrarese A, Passigato N, Cusumano C, Gemini S, Tonon A, Dajti E, Marasco G, Ravaioli F, Colecchia A (2021) Antibiotic prophylaxis in patients with cirrhosis: current evidence for clinical practice. World J Hepatol 13:840–852. https://doi.org/10.4254/wjh.v13.i8.840
Fukui H (2015) Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol 7:425–442. https://doi.org/10.4254/wjh.v7.i3.425
Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, Miranda ML, Llach J, Salmerón JM (1990) Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatol (Baltim Md) 12:716–724. https://doi.org/10.1002/hep.1840120416
Campillo B, Dupeyron C, Richardet JP (2001) Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 127:443–450. https://doi.org/10.1017/s0950268801006288
Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Karamanolis DG (2009) Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 29:992–999. https://doi.org/10.1111/j.1365-2036.2009.03958.x
Kimer N, Meldgaard M, Hamberg O, Kronborg TM, Lund AM, Møller HJ, Ytting H (2022) The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial. PLoS ONE 17:e0264278. https://doi.org/10.1371/journal.pone.0264278. (PMID: 35286322; PMCID: PMC8920190)
Kitagawa R, Kon K, Uchiyama A, Arai K, Yamashina S, Kuwahara-Arai K, Kirikae T, Ueno T, Ikejima K (2019) Rifaximin prevents ethanol-induced liver injury in obese KK-Ay mice through modulation of small intestinal microbiota signature. American journal of physiology. Gastrointest Liver Physiol 317:G707–G715. https://doi.org/10.1152/ajpgi.00372.2018
Sharma BC, Singh J (2016) Probiotics in management of hepatic encephalopathy. Metab Brain Dis 31:1295–1301. https://doi.org/10.1007/s11011-016-9826-x
McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC (2011) Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008716.pub2
Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, Shao T, Song Q, Zhu F, Zhang L, Jiang M, Zhou Y, Barve S, Zhang X, McClain CJ, Feng W (2020) Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. Hepatol (Baltim Md.) 71:2050–2066. https://doi.org/10.1002/hep.30975
Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M, Gillevet PM (2014) Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 39:1113–1125. https://doi.org/10.1111/apt.12695
Malyar RM, Naseri E, Li H, Ali I, Farid RA, Liu D, Chen X (2021) Hepatoprotective effects of selenium-enriched probiotics supplementation on heat-stressed wistar rat through anti-inflammatory and antioxidant effects. Biolog Trace Elem Res 199:3445–3456. https://doi.org/10.1007/s12011-020-02475-3. (PMID: 33161525)
Xia X, Chen J, Xia J, Wang B, Liu H, Yang L, Wang Y, Ling Z (2018) Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res 46:3596–3604. https://doi.org/10.1177/0300060518776064
Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S (2014) Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 12:1003–8.e1. https://doi.org/10.1016/j.cgh.2013.11.006
Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J (2021) Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hep Intl 15:36–50. https://doi.org/10.1007/s12072-021-10135-4
Malaguarnera G, Giordano M, Nunnari G, Bertino G, Malaguarnera M (2014) Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol 20:16639–16648. https://doi.org/10.3748/wjg.v20.i44.16639
Fukui H (2021) Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update. Gut and liver 15:666–676. https://doi.org/10.5009/gnl20032
Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, Romiti A, Candiani C, Capocaccia L (1990) Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. J Clin Gastroenterol 12:433–436. https://doi.org/10.1097/00004836-199008000-00016
Pandey KR, Naik SR, Vakil BV (2015) Probiotics, prebiotics and synbiotics- a review. J Food Sci Technol 52:7577–7587. https://doi.org/10.1007/s13197-015-1921-1
Vidot H, Cvejic E, Finegan LJ, Shores EA, Bowen DG, Strasser SI, McCaughan GW, Carey S, Allman-Farinelli M, Shackel NA (2019) Supplementation with synbiotics and/or branched chain amino acids in hepatic encephalopathy: a pilot randomised placebo-controlled clinical study. Nutrients 11:1810. https://doi.org/10.3390/nu11081810
Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM (2004) Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatol (Baltim Md) 39:1441–1449. https://doi.org/10.1002/hep.20194
McLellan AT, Lewis DC, O’Brien CP, Kleber HD (2000) Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284:1689–1695. https://doi.org/10.1001/jama.284.13.1689
Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S (2011) Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 108:3047–3052. https://doi.org/10.1073/pnas.1010529108
Ogbonnaya ES, Clarke G, Shanahan F, Dinan TG, Cryan JF, O’Leary OF (2015) Adult hippocampal neurogenesis is regulated by the microbiome. Biol Psychiat 78:e7–e9. https://doi.org/10.1016/j.biopsych.2014.12.023
Strandwitz P (2018) Neurotransmitter modulation by the gut microbiota. Brain Res 1693:128–133. https://doi.org/10.1016/j.brainres.2018.03.015
Tsavkelova EA, Botvinko IV, Kudrin VS, Oleskin AV (2000) Detection of neurotransmitter amines in microorganisms with the use of high-performance liquid chromatography. Dokl Biochem Proc Acad Sci USSR Biochem sec 372:115–117
Shishov VA, Kirovskaya TA, Kudrin VS, Oleskin AV (2009) Amine neuromediators, their precursors, and oxidation products in the culture of Escherichia coli K-12. Appl Biochem Microbiol 45:494–497. https://doi.org/10.1134/S0003683809050068
Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C (2012) γ-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 113:411–417. https://doi.org/10.1111/j.1365-2672.2012.05344.x
Cho YR, Chang JY, Chang HC (2007) Production of gamma-aminobutyric acid (GABA) by Lactobacillus buchneri isolated from kimchi and its neuroprotective effect on neuronal cells. J Microbiol Biotechnol 17:104–109
Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J (1999) Oxford textbook of clinical hepatology.
Pirovino M, Linder R, Boss C, Köchli HP, Mahler F (1988) Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr 66:298–302. https://doi.org/10.1007/BF01727516
Foutch PG, Sullivan JA, Gaines JA, Sanowski RA (1988) Cutaneous vascular spiders in cirrhotic patients: correlation with hemorrhage from esophageal varices. Am J Gastroenterol 83:723–726
Masoodi I, Farooq O, Singh R, Ahmad N, Bhat M, Wani A (2009) Courveilhier baumgarten syndrome: a rare syndrome revisited. Int J Health Sci 3:97–99 (PMID: 21475517)
MUEHRCKE RC (1956) The finger-nails in chronic hypoalbuminaemia: a new physical sign. Br Med J 1:1327–1328. https://doi.org/10.1136/bmj.1.4979.1327
Attali P, Ink O, Pelletier G, Vernier C, Jean F, Moulton L, Etienne JP (1987) Dupuytren’s contracture, alcohol consumption, and chronic liver disease. Arch Intern Med 147:1065–1067
Epstein O, Ajdukiewicz AB, Dick R, Sherlock S (1979) Hypertrophic hepatic osteoarthropathy. Clinical, roentgenologic, biochemical, hormonal and cardiorespiratory studies, and review of the literature. Am J Med 67:88–97. https://doi.org/10.1016/0002-9343(79)90078-0
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K (2021) Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 56:593–619. https://doi.org/10.1007/s00535-021-01788-x
Schiff ER, Maddrey WC, Reddy KR (eds.) (2017) Schiff’s diseases of the liver. John Wiley & Sons.
Del Campo JA, Gallego P, Grande L (2018) Role of inflammatory response in liver diseases: therapeutic strategies. World J Hepatol 10:1–7. https://doi.org/10.4254/wjh.v10.i1.1
Zhou WC, Zhang QB, Qiao L (2014) Pathogenesis of liver cirrhosis. World J Gastroenterol 20:7312–7324. https://doi.org/10.3748/wjg.v20.i23.7312
Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS (2013) Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 58:949–955. https://doi.org/10.1016/j.jhep.2013.01.003
Flamm SL (2011) Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Ther Adv Gastroenterol 4:199–206. https://doi.org/10.1177/1756283X11401774
Lv XY, Ding HG, Zheng JF, Fan CL, Li L (2020) Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study. World J Gastroenterol 26:199–218. https://doi.org/10.3748/wjg.v26.i2.199
Mendoza YP, Rodrigues SG, Bosch J, Berzigotti A (2020) Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: a systematic review and meta-analysis. Dig liver Dis Off J Italian Soc Gastroenterol Italian Assoc Study Liver 52:958–965. https://doi.org/10.1016/j.dld.2020.06.048
Li C, Meng M, Guo M, Wang M, Ju A, Wang C (2019) The polysaccharides from Grifola frondosa attenuate CCl4-induced hepatic fibrosis in rats via the TGF-β/Smad signaling pathway. RSC Adv 9:33684–33692. https://doi.org/10.1039/C9RA04679H
Wang K, Yang X, Wu Z, Wang H, Li Q, Mei H, You R, Zhang Y (2020) Dendrobium officinale polysaccharide protected CCl4-induced liver fibrosis through intestinal homeostasis and the LPS-TLR4-NF-κB signaling pathway. Front Pharmacol 11:240. https://doi.org/10.3389/fphar.2020.00240
Chiang YY, Chao JCJ (2018) Olive oil combined with Lycium barbarum polysaccharides attenuates liver apoptosis and inflammation induced by carbon tetrachloride in rats. J Funct Foods 48:329–336. https://doi.org/10.1016/j.jff.2018.07.029
Wang Z, Zhang X, Zhu L, Yang X, He F, Wang T, Bao T, Lu H, Wang H, Yang S (2020) Inulin alleviates inflammation of alcoholic liver disease via SCFAs-inducing suppression of M1 and facilitation of M2 macrophages in mice. Int Immunopharmacol 78:106062. https://doi.org/10.1016/j.intimp.2019.106062
Kumar R, Sood U, Gupta V, Singh M, Scaria J, Lal R (2020) Recent advancements in the development of modern probiotics for restoring human gut microbiome dysbiosis. Indian J Microbiol 60:12–25
Singhvi N, Gupta V, Gaur M, Sharma V, Puri A, Singh Y, Dubey GP, Lal R (2020) Interplay of human gut microbiome in health and wellness. Indian J microbiol 60:26–36
Author information
Authors and Affiliations
Contributions
The idea for the article was given by Nisha Kapoor. There is equal contribution of Aanchal Bharti and Isar Sharma for the conceptualization of study. Literature search and draft was prepared by Aanchal Bharti and Isar Sharma. Data analysis and revision was performed by Ritu Mahajan and Seema Langer. Article was critically revised by Nisha Kapoor.
Corresponding author
Ethics declarations
Conflict of Interest
The authors have no competing interests to declare that are relevant to the content of this article and have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bharti, A., Sharma, I., Mahajan, R. et al. From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?). Indian J Microbiol (2024). https://doi.org/10.1007/s12088-024-01267-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12088-024-01267-w